Michael Castagna is the CEO of MannKind Corporation, a role he has held since March 2016. He also serves on the company’s board of directors.
MannKind is a biopharmaceutical company focused on discovery, development, and commercialization of therapeutics for diseases like diabetes and pulmonary arterial hypertension. In his role as CEO, Dr. Castagna is focused on strategic development of the company’s people and products.
Dr. Castagna had a 14-year career as a pharmacist with CVS before fully transitioning to the business side of the industry. Before joining MannKind, he held various executive positions at Merck Serono, Sandoz, Pharmasett, Bristol-Myers Squibb, and most recently, Amgen, where he served as vice president, global commercial lead for a portfolio of nine biosimilar drugs.
While at BMS, he helped lead the relaunch of Orencia IV and the launch of Orencia SC, both drugs targeting rheumatoid arthritis. At Sandoz, he helped relaunch its lead product, a human growth hormone called Omnitrope.
In his free time, Castagna serves on the board of directors of Pet Partners, a nonprofit organization with a mission of improving people’s health through positive interactions with therapy animals.
He earned his B.S. in pharmacy from the University of the Sciences in Philadelphia, his M.B.A. in entrepreneurial studies from the University of Pennsylvania’s Wharton School of Business, and his doctor of pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences.
What is Michael Castagna's net worth?
The estimated net worth of Michael Castagna is at least $10.87 million as of June 1st, 2023. Dr. Castagna owns 2,516,735 shares of MannKind stock worth more than $10,872,295 as of June 7th. This net worth evaluation does not reflect any other investments that Dr. Castagna may own. Learn More about Michael Castagna's net worth.
What is Michael Castagna's salary?
As the CEO of MannKind Co., Dr. Castagna earned a total compensation package of $4,030,833.00 in 2021. Dr. Castagna earned a salary of $598,462.00, stock awards of $2,911,592.00, non-equity compensation of $481,762.00, and other compensation of $39,017.00. Learn More on Michael Castagna's salary.
How do I contact Michael Castagna?
Has Michael Castagna been buying or selling shares of MannKind?
During the past quarter, Michael Castagna has sold $1,167,600.00 in shares of MannKind stock. Most recently, Michael Castagna sold 10,000 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $4.53, for a transaction totalling $45,300.00. Following the completion of the sale, the chief executive officer now directly owns 2,516,735 shares of the company's stock, valued at $11,400,809.55. Learn More on Michael Castagna's trading history.
Who are MannKind's active insiders?
Are insiders buying or selling shares of MannKind?
In the last twelve months, MannKind insiders bought shares 5 times. They purchased a total of 18,100 shares worth more than $53,033.00. In the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 420,001 shares worth more than $1,934,326.13. The most recent insider tranaction occured on June, 1st when CEO Michael Castagna sold 10,000 shares worth more than $45,300.00. Insiders at MannKind own 4.0% of the company.
Learn More about insider trades at MannKind. Information on this page was last updated on 6/1/2023.
